Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 6, 2019; 7(15): 1964-1977
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1964
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1964
Figure 2 Patient flow chart.
HER2 positivity was observed in 127 (16.3%) of 776 patients with metastatic or unresectable adenocarcinoma. After exclusion of 39 patients for the listed reasons, HER2 homogeneity was observed in 65 (Homo group) and HER2 heterogeneity was observed in 23 (Hetero group). HER2: Human epidermal growth factor receptor 2.
- Citation: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977
- URL: https://www.wjgnet.com/2307-8960/full/v7/i15/1964.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i15.1964